Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus

H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation

S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

L Elens, R Bouamar, DA Hesselink, V Haufroid… - Clinical …, 2011 - academic.oup.com
BACKGROUND Tacrolimus (Tac) is a potent immunosuppressant with considerable toxicity.
Tac pharmacokinetics varies between individuals and thus complicates its use in preventing …

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients

AHIM Ebid, DA Ismail, NM Lotfy… - Journal of Clinical …, 2022 - Wiley Online Library
Background Tacrolimus is a widely prescribed immunosuppressant agent for kidney
transplantation. However, optimal dosing is challenging due to its narrow therapeutic index …

Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype‐guided doses in renal …

S Anutrakulchai, C Pongskul… - British Journal of …, 2019 - Wiley Online Library
Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …

Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

E Thervet, D Anglicheau, B King, MH Schlageter… - …, 2003 - journals.lww.com
Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta …

AR Khan, A Raza, S Firasat, A Abid - The Pharmacogenomics Journal, 2020 - nature.com
Tacrolimus is an immunosuppressive drug widely used in kidney transplantation.
Cytochrome P450 3A5 (CYP3A5) protein is involved in tacrolimus metabolism. Single …

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

B Tavira, EC Garciá, C Díaz-Corte, F Ortega… - Clinical chemistry and …, 2011 - degruyter.com
Abstract Background: Tacrolimus (Tac) is an immunosuppressive drug used to prevent post-
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism–a prospective, randomized, controlled study

SY Chen, JL Li, FH Meng, XD Wang, T Liu… - Clinical …, 2013 - Wiley Online Library
We investigated how cytochrome P450 (CYP) 3A5 polymorphism affects pharmacokinetics
of tacrolimus and its interaction with diltiazem in Chinese kidney transplant recipients. Sixty …